Rosetta Genomics Ltd. (NASDAQ:ROSG) major shareholder Healthcare Master Fund Sabby bought 119,761 shares of the firm’s stock in a transaction dated Thursday, March 15th. The shares were acquired at an average price of $0.42 per share, for a total transaction of $50,299.62. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Healthcare Master Fund Sabby also recently made the following trade(s):
- On Tuesday, March 13th, Healthcare Master Fund Sabby bought 175,828 shares of Rosetta Genomics stock. The shares were acquired at an average price of $0.42 per share, for a total transaction of $73,847.76.
Rosetta Genomics Ltd. (NASDAQ:ROSG) traded up $0.02 during trading on Friday, reaching $0.44. The company had a trading volume of 343,353 shares, compared to its average volume of 160,476. Rosetta Genomics Ltd. has a fifty-two week low of $0.23 and a fifty-two week high of $4.41. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.03.
Several analysts have recently commented on the company. ValuEngine upgraded Rosetta Genomics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Barrington Research cut Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th.
WARNING: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/18/rosetta-genomics-ltd-rosg-major-shareholder-acquires-50299-62-in-stock.html.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests-based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.